Expert Review of Respiratory Medicine, Год журнала: 2024, Номер unknown, С. 1 - 15
Опубликована: Окт. 30, 2024
Chronic Obstructive Pulmonary Disease (COPD) significantly predisposes the elderly to pneumonia, presenting a complex interplay of pulmonary dysfunction and infection risk.
Язык: Английский
Respiratory Research, Год журнала: 2024, Номер 25(1)
Опубликована: Авг. 5, 2024
Abstract Background Japanese guidelines recommend triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β 2 -agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) and no concurrent asthma diagnosis who experience frequent exacerbations have blood eosinophil (EOS) count ≥ 300 cells/mm 3 , COPD continuing/worsening symptoms despite receiving dual ICS/LABA therapy. These post-hoc analyses of the KRONOS study without an diagnosis, examine effects fixed-dose budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) versus therapies on lung function based EOS – focusing 100 to < as a exacerbation history severity. Methods In KRONOS, were randomized receive treatments that included BGF 320/14.4/10 µg, glycopyrronium/formoterol (GFF) 14.4/10 or budesonide/formoterol (BFF) 320/10 µg via metered dose inhaler (two inhalations twice-daily for 24 weeks). assessed changes from baseline morning pre-dose trough forced expiratory volume 1 s (FEV ) over 12–24 weeks moderate severe rates weeks. The was not prospectively powered these subgroup analyses. Results Among least squares mean treatment differences improvement favored BFF past year COPD, observed ranging 62 ml 73 across populations. this same population, reduced relative GFF by 56% year, 47% 50% COPD. Conclusions moderate-to-very seem indicate clinicians may want consider step-up persistent/worsening > even if severity is there recent exacerbations. Trial registration ClinicalTrials.gov registry number NCT02497001 (registration date, 13 July 2015).
Язык: Английский
Процитировано
10
Expert Review of Respiratory Medicine, Год журнала: 2025, Номер unknown
Опубликована: Фев. 10, 2025
Introduction Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality worldwide, primarily due to persistent airflow limitation from tobacco and biomass smoke exposure. While inhaled corticosteroids (ICS) combined with long-acting bronchodilators, namely β2-adrenoreceptor agonists (LABA) muscarinic antagonists (LAMA), are recommended for symptom control exacerbation reduction, their effect on remains uncertain. Recent randomized controlled trials (RCTs) suggest potential benefits triple ICS/LABA/LAMA therapy, though findings not definitive.
Язык: Английский
Процитировано
0
Expert Opinion on Pharmacotherapy, Год журнала: 2024, Номер unknown, С. 1 - 20
Опубликована: Сен. 29, 2024
Chronic obstructive pulmonary disease (COPD) is a common syndrome associated with smoking and environmental exposures coupled genetic susceptibility. Recent major advancements in the treatment of COPD patients have become available.
Язык: Английский
Процитировано
4
Journal of Thoracic Disease, Год журнала: 2025, Номер 17(3), С. 1228 - 1248
Опубликована: Март 1, 2025
Chronic obstructive pulmonary disease (COPD) is a long-term respiratory condition defined by ongoing symptoms and restricted airflow, resulting in high rates of morbidity, mortality, disability for this condition. Due to the incomplete understanding its pathogenesis, no permanent curative measures or specific drugs are available. In recent years, multitude research has highlighted substantial influence oxidative stress on development COPD; however, there been deficiency bibliometric analyses focusing trends hotspots field. Therefore, our study aimed at presenting emerging related COPD stress. Publications concerning were obtained from Web Science Core Collection database, covering period 2010 2024. On July 25, 2024, all relevant data downloaded, followed process screening analysis. The analysis incorporated 1,308 articles 440 reviews, involving contributions 1,034 researchers affiliated with 512 institutions across 64 countries published total 548 journals. Through series using five visualization tools, we identified top 5 most productive countries, institutions, journals, highly co-cited journals field We also 12 citation clusters, 10 influential authors, authors articles, 11 keyword established 20 keywords, observed evolution reference bursts. This first quantitatively capture progress research, results show marked upward trend years terms Developing novel effective antioxidants becoming future direction treatment. Besides antioxidant therapy, exposure (to air pollution), cigarette smoke, mitochondrial dysfunction emerged as prominent hotspots. extensive offers significant insights into exploration publications purpose support enhance scientific investigators
Язык: Английский
Процитировано
0
EBioMedicine, Год журнала: 2025, Номер 115, С. 105707 - 105707
Опубликована: Апрель 16, 2025
Язык: Английский
Процитировано
0
Biomedicines, Год журнала: 2024, Номер 12(2), С. 372 - 372
Опубликована: Фев. 5, 2024
Recommendations for the treatment of chronic obstructive pulmonary disease (COPD) have shifted towards a more restrictive use inhaled corticosteroids (ICS). We aimed to identify nationwide development over time in ICS COPD. conducted register-based repeated cross-sectional study using Danish registers. On yearly basis from 1998 2018, we included all patients Denmark ≥ 40 years age with an ICD-10 diagnosis COPD (J44). Accumulated was calculated each year based on redeemed prescriptions. Patients were divided into following groups: No ICS, low-dose medium-dose or high-dose ICS. From proportion without increased (from 50.6% 57.6%), 11.3% 14.9%), and decreased 17.0% 9.4%). demonstrated national reduction increase decrease treatment.
Язык: Английский
Процитировано
3
Respiratory Research, Год журнала: 2024, Номер 25(1)
Опубликована: Янв. 18, 2024
Randomised control trials (RCTs) with strict eligibility criteria can lead to trial populations not commonly seen in clinical practice. We described the proportion of people chronic obstructive pulmonary disease (COPD) England eligible for RCTs investigating treatment triple therapy. MEDLINE and Clinicaltrials.gov were searched therapy each extracted. Using routinely collected primary care data from Clinical Practice Research Datalink Aurum linked Hospital Episode Statistics, we defined a population COPD patients registered at general practice England, who ≥ 40 years old, had history smoking. Inclusion date was January 1, 2020. Patients died earlier or left excluded. Eligibility RCT applied meeting described. 26 identified literature. The most common post-bronchodilator FEV1% predicted 30-80%, 2 moderate/≥ 1 severe exacerbations 12-months prior, no moderate one-month prior three-months use maintenance ICS inclusion. After applying our 79,810 patients, median 11.2% [interquartile range (IQR) 1.8-17.4] met criteria. discriminatory included presence previous related medication 67.6% (IQR 8.5-73.4) 63% 69.3-38.4) these criteria, respectively. Data may be generalisable wider everyday real-world evidence studies are needed supplement understand effectiveness all COPD.
Язык: Английский
Процитировано
2
Pharmaceutics, Год журнала: 2024, Номер 16(10), С. 1318 - 1318
Опубликована: Окт. 11, 2024
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, particularly in low- middle-income countries, where it poses significant burden. In Latin America, the estimated prevalence COPD notably high, but management treatment have progressed slowly. This review examines current status inhalation therapy for focusing on pharmacological therapies, devices, potential advanced drug delivery systems. Pharmacological predominantly relies inhaled bronchodilators corticosteroids, though access to these therapies varies considerably across region. Inhalation such as metered-dose inhalers (MDIs) dry powder (DPIs), play critical role effective delivery. However, their usage often compromised by incorrect technique, low adherence, limited availability, especially DPIs. Emerging technologies, including nanoformulations, represent promising frontier improving reducing side effects. barriers, high development costs inadequate infrastructure, hinder widespread adoption highlights need multifaceted approach enhance optimizing existing strengthening healthcare provider training, engaging patients decisions. Overcoming challenges crucial outcomes
Язык: Английский
Процитировано
2
Journal of Cellular and Molecular Medicine, Год журнала: 2024, Номер 28(20)
Опубликована: Окт. 1, 2024
Abstract The role of eosinophilic inflammation in the pathogenesis chronic obstructive pulmonary disease (COPD) remains ambiguous and likely differs from its asthma. molecular processes underlying differences between eosinophils asthma COPD have not been sufficiently studied. objective this study was to compare transcriptomic profiles blood Eosinophils were isolated peripheral drawn stable mild‐to‐moderate patients. RNA sequenced using an NGSelect RNA. prepared libraries on Illumina platform. group included five patients with four COPD. RNA‐Seq data analysis identified 26 differentially expressed genes (according adjusted p ‐value). In total, 6 upregulated (e.g. CCL3L1 , CCL4L2 GPR82 ) 20 downregulated JUN IFITM3 DUSP1 GNG7 compared associated signalling IL‐4 IL‐13 pathways conclusion, present different suggesting their function pathobiology both airway diseases. These might indicate direction search targeted therapy
Язык: Английский
Процитировано
2
International Journal of Clinical Pharmacy, Год журнала: 2024, Номер 46(4), С. 831 - 842
Опубликована: Апрель 25, 2024
Язык: Английский
Процитировано
1